Visa and Anchorage Digital are backing Western Union's USDPT stablecoin as a settlement asset on Visa's network, where stablecoin settlements have reached an annualized volume of $25 billion. USDPT is issued by Western Union and can be used by Visa and its partners to settle payments. Over 225 stablecoin-linked card programs are active globally, and Visa's stablecoin settlement volume has grown tenfold, highlighting the increasing adoption of digital assets in payment systems.
Visa and Anchorage's backing of Western Union's USDPT stablecoin comes as stablecoin settlements on Visa's network have reached an annualized volume of $25 billion. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Nov 13, 2026 07:31 WIB: out of 50 major cryptocurrencies, 21 rose and 28 fell today. Notable movers include AAVE at Rp2.080.482 with a 3% Sell / 97% Buy order activity, ZIL at Rp27 with 40% Sell / 60% Buy, and ONE at Rp28 with 40% Sell / 60% Buy.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Reviva Pharmaceuticals announced it expects FDA feedback in Q4 2026 on a new formulation of brilaroxazine for its RECOVER-2 Phase 3 trial targeting schizophrenia. The company plans to start a bioequivalence study in Q1 2027 and begin patient enrollme...
